Focus: Hyperfine develops portable MRI scanner technology focused on point-of-care brain imaging, particularly for neurology and oncology applications. The company is commercializing its Swoop portable MRI system with early international adoption signals.
Profile data last refreshed 17h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Best for early-stage device/hardware engineers and software professionals seeking to build novel diagnostic infrastructure; financial stability and long-term career ladder remain uncertain.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Hyperfine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hyperfine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Hyperfine’s portable MRI system demonstrates time-saving benefit in new data readout - Clinical Trials Arena
Hyperfine’s portable MRI system demonstrates time-saving benefit in new data readout Clinical Trials Arena
8-K Filing: Profound Medical Corp. (PROF) (CIK 0001628808) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: Hyperfine, Inc. (HYPR) (CIK 0001833769) — EX-99.1
EX-99.1
AIIMS Delhi Introduces Hyperfine Swoop System, India’s First Portable MRI for Bedside Brain Imaging - Digital Health News
AIIMS Delhi Introduces Hyperfine Swoop System, India’s First Portable MRI for Bedside Brain Imaging Digital Health News
DRADS Capital - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn
DRADS Capital - 2026 Investor Profile, Portfolio, Team & Investment Trends Tracxn
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo